This discrepancy may be due to the following reasons: the included population mostly consists of patients with obesity or MetS (with low baseline adiponectin levels), short intervention duration (<6 months), and uncontrolled confounding factors such as diet and medication. This evidence concerns the gene ADIPOQ and metabolic syndrome.